Skip to navigation Skip to content

Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised patisiran for patients with hereditary transthyretin amyloidosis (HTA).

HTA and listing dates

HTA is a hereditary condition characterised by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Listing date: patisiran - 1 August 2024.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link
  • FAQs from Service Officers

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority approval requests

Written Authority Required Drugs